Temperature and pH sensitive hydrogels: An approach towards smart semen-triggered vaginal microbicidal vehicles

Journal of Pharmaceutical Sciences

Volumn 96, Issue 3, 2007, Pages 670-681

  Gupta, Kavita M ^a   Barnes, Scott R ^a   Tangaro, Rachel A ^a   Roberts, Meredith C ^a   Owen, Derek H ^b   Katz, David F ^b   Kiser, Patrick F ^a  

^a Department of Electrical and Computer Engineering   (United States)

^b Duke University   (United States)

Author keywords

Controlled release delivery; Formulation vehicle; HIV AIDS; Microbicide; Responsive delivery system; Retention; Semen triggered drug release; Thermal gels; Vaginal coating; Viscosity

Indexed keywords

ACRYLAMIDE DERIVATIVE; ACRYLIC ACID; CARBOMER; DRUG VEHICLE; METHACRYLIC ACID BUTYL ESTER; METHACRYLIC ACID DERIVATIVE; MICROBICIDE; N ISOPROPYL ACRYLAMIDE; POLYMER; TERPOLYMER; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; FLOW KINETICS; HEAT SENSITIVITY; HYDROGEL; PH; POLYMERIZATION; SPERM; TEMPERATURE;

EID: 33947503596     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20752     Document Type: Article

References (41)

1. UNAIDS. 2004. Women and AIDS, confronting the crisis.
2. UNAIDS. 2004. Questions & answers II: Basic facts about the HIV/AIDS epidemic and its impact.
3. Shattock RJ, Moore JP. 2003. Inhibiting sexual transmission of HIV-1 infection. Nature Rev Microbiol 1:25-34.
4. Stone A. 2002. Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov 1:977-985.
5. Watts CMCO. 2002. The public health impact of microbicides: Model projections. Microbicides 2002 Conference [online].
6. Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, Patterson BK, Coombs RW, Krieger JN, Cohen MS. 2001. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: A probabilistic empiric model. Aids 15:621-627.
7. Dyer JR, Kazembe P, Vernazza PL, Gilliam BL, Maida M, Zimba D, Hoffman IF, Royce RA, Schock JL, Fiscus SA, Cohen MS, Eron JJ, Jr. 1998. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 177:1742-1746.
8. Okada H, Hillery AM. 2001. Vaginal drug delivery, 1st ed., NY: Taylor and Francis Inc. pp 301-328.
9. Owen DH, Katz DF. 1999. A vaginal fluid simulant. Contraception 59:91-95.
10. Owen DH, Katz DF. 2005. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl 26:459-469.
11. Tevi-Benissan C, Belec L, Levy M, Schneider-Fauveau V, Si Mohamed A, Hallouin MC, Matta M, Gresenguet G. 1997. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol 4:367-374.
12. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. 2005. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 56:954-956.
13. Woolfson AD, Malcolm RK, Toner CF, Morrow RJ, Lowry D, Jamil A, McCullagh SD. 2006. Potential use of vaginal rings for prevention of heterosexual transmission of HIV: A controlled-release strategy for HIV microbicides. Am J Drug Deliv 4:7-20.
14. das Neves J, Bahia MF. 2006. Gels as vaginal drug delivery systems. Int J Pharm 318:1-14.
15. Garg S, Vermani K, Garg A, Anderson RA, Rencher WB, Zaneveld LJ. 2005. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res 22:584-595.
16. Mauck CK, Baker JM, Barr SP, Abercrombie TJ, Archer DF. 1997. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy. Contraception 56:89-96.
17. Neurath AR, Strick N, Li YY. 2003. Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect Dis 3:27.
18. Rustomjee R, Abdool Karim Q, Abdool Karim SS, Laga M, Stein Z. 1999. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. Aids 13:1511-1515.
19. Garg S, Tambwekar KR, Vermani K, Kandarapu R, Garg A, Waller DP, Zaneveld LJ. 2003. Development pharmaceutics of microbicide formulations. Part II: Formulation, evaluation, and challenges. AIDS Patient Care STDS 17:377-399.
20. Geonnotti AR, Peters JJ, Katz DF. 2005. Erosion of microbicide formulation coating layers: Effects of contact and shearing with vaginal fluid or semen. J Pharm Sci 94:1705-1712.
21. Lard-Whiteford SL, Matecka D, O'Rear JJ, Yuen IS, Litterst C, Reichelderfer P. 2004. Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: An update. J Acquir Immune Defic Syndr 36:541-552.
22. Achilles SL, Shete PB, Whaley KJ, Moench TR, Cone RA. 2002. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis 29:655-664.
23. Garg S, Tambweker KR, Vermani K, Garg A, Kaul CL, Zaneveld LJ. 2001. Compendium of pharmaceutical excipients for vaginal formulations. Pharm Technol Drug Deliv 11:14-24.
24. Owen DH, Peters JJ, Katz DF. 2000. Rheological properties of contraceptive gels. Contraception 62:321-326.
25. Peterson L, Toxler A, Belai G. 2006. Microbicides 2006, Cape Town, South Africa, 2006, OD13.
26. Bergeron MG, Gagne N, Gourde P, Perron S, Tremblay M, Juhasz J, Beauchamp D, Desormeaux A. 1997. Using microbicidal gels to prevent sexual transmission of HIV. Polymeric Mater Scie Eng 76:278.
27. Chang JY, Oh YK, Choi HG, Kim YB, Kim CK. 2002. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int J Pharm 241:155-163.
28. Kim YHB, Kim SW. 1994. pH/Temperature-sensitive polymers for macromolecular drug loading and release. J Control Release 28:143-152.
29. Hoffman AS, Afrassiabi A, Dong LC. 1986. Thermally reversible hydrogels: II. Delivery and selective removal of substances from aqueous solutions. J Control Release 4:213-222.
30. Kimerling AS, Rochefort WE, Bhatia SR. 2006. Rheology of block polyelectrolyte solutions and gels: A review. Ind Eng Chem Res 45:6885-6889.
31. About 1 mm layer of the sample was loaded in a 4 mL vial maintained at 37°C for 10 min prior to loading the sample. The time required for the sample layer to reach 37°C was recorded. The experiment was repeated three times and the mean value of the three time measurements was used (data not shown).
32. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
33. Olmsted SS, Khanna KV, Ng EM, Whitten ST, Johnson ON III, Markham RB, Cone RA, Moench TR. 2005. Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis 5:79.
34. Owen DH, Peters JJ, Lavine ML, Katz DF. 2003. Effect of temperature and pH on contraceptive gel viscosity. Contraception 67:57-64.
35. Hoffman IF, Taha TE, Padian NS, Kelly CW, Welch JD, Martinson FE, Kumwenda NI, Rosenberg ZF, Chilongozi DA, Brown JM, Chirenje M, Richardson BA. 2004. Nonoxynol-9 100 mg gel: Multi-site safety study from sub-Saharan Africa. Aids 18:2191-2195.
36. The United States Pharmacopeia. XXVI rev; 2002. United States Pharmacopeial Convention, Inc.: Rockville, MD, pp 1831-1836.
37. Krebs FC, Miller SR, Catalone BJ, Fichorova R, Anderson D, Malamud D, Howett MK, Wigdahl B. 2002. Comparative in vitro sensitivities of human immune cell lines, vaginal and cervical epithelial cell lines, and primary cells to candidate microbicides nonoxynol 9, C31G, and sodium dodecyl sulfate. Antimicrob Agents Chemother 46:2292-2298.
38. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, Weber J, Kitchen VS. 1998. Safety study of nonoxynol-9 as a vaginal microbicide: Evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 17:327-331.
39. Roddy RE, Cordero M, Cordero C, Fortney JA. 1993. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 4:165-170.
40. van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K. 2001. Phase 1 trial of the topical microbicide BufferGel: Safety results from four international sites. J Acquir Immune Defic Syndr 26:21-27.
41. Doncel GF, Chandra N, Fichorova RN. 2004. Preclinical assessment of the proinflammatory potential of microbicide candidates. J Acquir Immune Defic Syndr 37:S174-S180.